Wedbush Morgan Upgrades Halozyme Therapeutics (HALO) to Outperform
More News related to HALO
- ProMetic and Halozyme Enter Into Long-Term Supply Agreement
- Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme
- Halozyme (HALO) posts Q3 Loss of 16c, Beats by 2c
- Halozyme Therapeutics Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/06: American International (AIG), Scripps (SNI), Suncor Energy (SU), Blackstone Group (BX) Report
More News related to RHHBY
- Inhibition of Cell Migration by Gene Silencing - Measured with the xCELLigence Cell Analysis System from Roche
- Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
- 454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System Including 1,000 bp Reads for 2010
- New Cancer Research Tool: Roche's CIM-Plate 16 Enables Real-Time Analysis of Cell Migration on the xCELLigence System
- Eurofins MWG Operon Joins Roche NimbleGen's Certified Service Provider Program for Targeted Enrichment and Sequencing Services
More News related to Upgrades
- Davenport Upgrades Heinz (HNZ) to Buy
- First Analysis Upgrades Advisory Board Company (ABCO) to Overweight
- Jefferies & Co Upgrades Energy XXI (EXXI) to Hold
- Morgan Stanley Upgrades Iowa Telecom (IWA) to Equalweight
- Fox-Pitt Upgrades Eaton Vance (EV) to Outperform
Wedbush Morgan upgrades Halozyme Therapeutics, Inc. (Nasdaq: HALO) from Neutral to Outperform. Price target increased from $7 to $10.
Wedbush analyst says, "We believe that shortly, Roche (OTC: RHHBY) will announce the initiation of the Phase III study for their lead program under the Halozyme Enhanze deal (we believe it is HERCEPTIN). We do not think that Roche would have started what we believe is the third program with the technology (subcutaneous RITUXAN Phase I) if the data from the subcutaneous HERCEPTIN and subcutaneous ACTEMRA Phase I studies were negative. Based upon our anticipation that Roche will go into Phase III, which we derive by Roche continuing new studies and the time from completion of the first Phase I study, we believe that Roche will announce the initiation of the Phase III and the name of the drug by YE:09."
To see more analyst ratings on HALO Click Here.
Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets.
Related Categories
UpgradesStocks Mentioned
-0.14
+0.84Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
